vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是Rapid7, Inc.的1.9倍（$406.6M vs $217.4M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 1.4%，领先59.0%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 0.5%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $36.4M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 3.0%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
BCRX vs RPD — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $217.4M |
| 净利润 | $245.8M | $3.1M |
| 毛利率 | 97.7% | 68.9% |
| 营业利润率 | 64.0% | 1.0% |
| 净利率 | 60.5% | 1.4% |
| 营收同比 | 209.1% | 0.5% |
| 净利润同比 | 1017.5% | 44.1% |
| 每股收益（稀释后） | $1.13 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $217.4M | ||
| Q3 25 | $159.4M | $218.0M | ||
| Q2 25 | $163.4M | $214.2M | ||
| Q1 25 | $145.5M | $210.3M | ||
| Q4 24 | $131.5M | $216.3M | ||
| Q3 24 | $117.1M | $214.7M | ||
| Q2 24 | $109.3M | $208.0M | ||
| Q1 24 | $92.8M | $205.1M |
| Q4 25 | $245.8M | $3.1M | ||
| Q3 25 | $12.9M | $9.8M | ||
| Q2 25 | $5.1M | $8.3M | ||
| Q1 25 | $32.0K | $2.1M | ||
| Q4 24 | $-26.8M | $2.2M | ||
| Q3 24 | $-14.0M | $15.4M | ||
| Q2 24 | $-12.7M | $6.5M | ||
| Q1 24 | $-35.4M | $1.4M |
| Q4 25 | 97.7% | 68.9% | ||
| Q3 25 | 98.6% | 70.2% | ||
| Q2 25 | 98.3% | 70.6% | ||
| Q1 25 | 96.9% | 71.7% | ||
| Q4 24 | 95.4% | 69.5% | ||
| Q3 24 | 97.3% | 70.6% | ||
| Q2 24 | 98.4% | 70.7% | ||
| Q1 24 | 98.6% | 70.3% |
| Q4 25 | 64.0% | 1.0% | ||
| Q3 25 | 18.6% | 2.7% | ||
| Q2 25 | 18.2% | 1.6% | ||
| Q1 25 | 14.6% | -0.0% | ||
| Q4 24 | -3.4% | 3.4% | ||
| Q3 24 | 6.6% | 6.0% | ||
| Q2 24 | 8.0% | 2.5% | ||
| Q1 24 | -15.6% | 4.7% |
| Q4 25 | 60.5% | 1.4% | ||
| Q3 25 | 8.1% | 4.5% | ||
| Q2 25 | 3.1% | 3.9% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | -20.4% | 1.0% | ||
| Q3 24 | -12.0% | 7.2% | ||
| Q2 24 | -11.6% | 3.1% | ||
| Q1 24 | -38.1% | 0.7% |
| Q4 25 | $1.13 | $0.05 | ||
| Q3 25 | $0.06 | $0.15 | ||
| Q2 25 | $0.02 | $0.13 | ||
| Q1 25 | $0.00 | $0.03 | ||
| Q4 24 | $-0.13 | $0.08 | ||
| Q3 24 | $-0.07 | $0.21 | ||
| Q2 24 | $-0.06 | $0.09 | ||
| Q1 24 | $-0.17 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $154.7M |
| 总资产 | $514.2M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $474.7M | ||
| Q3 25 | $212.9M | $407.1M | ||
| Q2 25 | $260.0M | $511.7M | ||
| Q1 25 | $295.1M | $493.5M | ||
| Q4 24 | $320.9M | $521.7M | ||
| Q3 24 | $96.8M | $443.7M | ||
| Q2 24 | $78.4M | $442.6M | ||
| Q1 24 | $84.3M | $411.7M |
| Q4 25 | $-119.2M | $154.7M | ||
| Q3 25 | $-387.9M | $127.2M | ||
| Q2 25 | $-421.6M | $90.4M | ||
| Q1 25 | $-451.9M | $52.7M | ||
| Q4 24 | $-475.9M | $17.7M | ||
| Q3 24 | $-468.6M | $-5.1M | ||
| Q2 24 | $-475.6M | $-52.6M | ||
| Q1 24 | $-476.2M | $-86.4M |
| Q4 25 | $514.2M | $1.7B | ||
| Q3 25 | $446.4M | $1.7B | ||
| Q2 25 | $457.2M | $1.6B | ||
| Q1 25 | $480.0M | $1.6B | ||
| Q4 24 | $490.4M | $1.7B | ||
| Q3 24 | $491.3M | $1.6B | ||
| Q2 24 | $472.4M | $1.5B | ||
| Q1 24 | $467.9M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $36.4M |
| 自由现金流率自由现金流/营收 | 71.6% | 16.8% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.19× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $344.9M | $146.2M |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $37.6M | ||
| Q3 25 | $41.6M | $39.0M | ||
| Q2 25 | $41.3M | $47.5M | ||
| Q1 25 | $-27.5M | $29.8M | ||
| Q4 24 | $-5.2M | $63.8M | ||
| Q3 24 | $8.2M | $44.0M | ||
| Q2 24 | $-1.4M | $32.9M | ||
| Q1 24 | $-53.7M | $31.1M |
| Q4 25 | $291.2M | $36.4M | ||
| Q3 25 | $40.3M | $34.8M | ||
| Q2 25 | $41.1M | $46.6M | ||
| Q1 25 | $-27.7M | $28.4M | ||
| Q4 24 | $-5.9M | $62.6M | ||
| Q3 24 | $8.2M | $42.6M | ||
| Q2 24 | $-1.5M | $32.6M | ||
| Q1 24 | $-53.9M | $30.4M |
| Q4 25 | 71.6% | 16.8% | ||
| Q3 25 | 25.3% | 16.0% | ||
| Q2 25 | 25.2% | 21.8% | ||
| Q1 25 | -19.0% | 13.5% | ||
| Q4 24 | -4.5% | 28.9% | ||
| Q3 24 | 7.0% | 19.9% | ||
| Q2 24 | -1.4% | 15.7% | ||
| Q1 24 | -58.1% | 14.8% |
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.8% | 1.9% | ||
| Q2 25 | 0.1% | 0.4% | ||
| Q1 25 | 0.1% | 0.6% | ||
| Q4 24 | 0.5% | 0.5% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.3% | 0.3% |
| Q4 25 | 1.19× | 12.01× | ||
| Q3 25 | 3.23× | 3.97× | ||
| Q2 25 | 8.12× | 5.70× | ||
| Q1 25 | -859.91× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
